Innoviva (INVA) Finished Goods (2013 - 2026)
Innoviva's (INVA) quarterly Finished Goods came in at $4.1 million in Q1 2026, up 18.17% YoY from $3.4 million in Q1 2025, and down 18.35% on a QoQ basis from $5.0 million in Q4 2025.
Analysis
Innoviva (INVA) Finished Goods (2013 - 2026) Analysis & Trends
Innoviva (INVA) has 7 years of Finished Goods data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Finished Goods rose 18.17% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 18.17% YoY) and the FY2025 annual result came in at $5.0 million, up 138.65% from the prior year.
- Finished Goods eased to $4.1 million in Q1 2026, from $5.0 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $25.1 million in Q4 2022 to a low of $2.1 million in Q4 2024.
- A 5-year average of $9.6 million and a median of $5.3 million in 2025 frame the typical range for Finished Goods.
- Annual changes were most pronounced in 2024 — Finished Goods sank 84.92% — and 2025, when it surged 138.65%.
- Tracing INVA's Finished Goods over 5 years: stood at $25.1 million in 2022, then plunged by 44.95% to $13.8 million in 2023, then tumbled by 84.92% to $2.1 million in 2024, then surged by 138.65% to $5.0 million in 2025, then slipped by 18.35% to $4.1 million in 2026.
- The last three Finished Goods figures came in at $4.1 million (Q1 2026), $5.0 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.12 Mn |
| Mar 31, 2026 | 4.06 Mn |
| Dec 31, 2025 | 4.97 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Jun 30, 2025 | 4.30 Mn |
| Mar 31, 2025 | 3.44 Mn |
| Dec 31, 2024 | 2.08 Mn |
| Sep 30, 2024 | 4.31 Mn |
| Jun 30, 2024 | 4.34 Mn |
| Mar 31, 2024 | 7.72 Mn |
| Dec 31, 2023 | 13.81 Mn |
| Sep 30, 2023 | 18.43 Mn |
| Jun 30, 2023 | 14.12 Mn |
| Mar 31, 2023 | 21.36 Mn |
| Dec 31, 2022 | 25.09 Mn |
| Sep 30, 2022 | 10.92 Mn |
| Mar 31, 2014 | 4.79 Mn |
| Dec 31, 2013 | 4.91 Mn |
| Sep 30, 2013 | 1.35 Mn |